The North America myopia treatment market was valued at US$ 3,938.90 million in 2022 and is expected to reach US$ 7,335.26 million by 2030; it is estimated to register a CAGR of 8.1% from 2022 to 2030.

Rising Prevalence of Myopia Fuels North America Myopia Treatment Market

The rising prevalence of myopia globally represents a significant public health concern, with increasing incidences observed among children and young adults, particularly. A recent study estimated that by 2050, nearly 50% of the world's population-or 5 billion people-will be myopic, up from the current average of 30%. The frequency of myopia is also increasing in the US; it has been reported to be 42%, nearly doubling in just three decades. Multiple factors contribute to this trend, including lifestyle changes, increased urbanization, and extensive near-work activities, such as prolonged use of digital devices and limited outdoor exposure. While genetic predisposition plays a role, environmental factors also contribute to escalating the rates of myopia substantially. The impact of these lifestyle and environmental factors has led to an enhanced understanding of the complex interplay between genetic susceptibility and environmental influences, further underscoring the need for comprehensive strategies to address this burgeoning public health issue. As the prevalence of myopia continues to rise, there is a growing emphasis on developing proactive interventions, public health campaigns, and innovative treatment approaches to mitigate the long-term implications of high myopia and its associated ocular complications, thereby emphasizing the importance of addressing this multifaceted global health challenge.

North America Myopia Treatment Market Overview

The North America myopia treatment market has been segmented into the US, Canada, and Mexico. The US holds the largest share of the North America myopia treatment market. The market growth in the US will be due to factors such as the growing myopia-related occurrences of vision loss and rising incidence of distant vision impairment from untreated myopia. Furthermore, the rising government support for eye health and technological advancements are prominent factors propelling the North America market growth.

The US myopia treatment market is expected to experience significant growth in the coming years. The prevalence of myopia has been increasing in recent years, which is driving the demand for effective treatments. The US has reported a prevalence of 42%, nearly doubling in just three decades, according to data released by the Myopia Institute in 2023. Furthermore, increasing awareness about myopia is also driving market growth. For instance, the Brien Holden Vision Institute's 2024 Myopia Awareness Week has selected Review of Myopia Management as its official co-sponsor. The collaboration will assist in expanding the reach of Myopia Awareness Week, which is scheduled for domestically and internationally, May 13-19, 2024. More people are becoming aware of the risks associated with myopia, such as an increased risk of developing other eye conditions-cataracts and glaucoma. This has led to a greater demand for effective treatments that can help prevent or slow down the progression of myopia. Another factor driving the growth of the myopia treatment market in the US is the availability of advanced technologies and treatments. Various treatments for myopia are now available, including corrective lenses, orthokeratology, and pharmacological treatments. These treatments are becoming increasingly sophisticated and effective, helping drive demand for myopia treatment. Finally, the growing prevalence of myopia among children is also driving the growth of the myopia treatment market in the US. As more children are diagnosed with myopia, there is a greater need for effective treatments that can help prevent or slow down its progression. This has led to increased investment in research and development of new treatments specifically designed for children. Overall, the US myopia treatment market is expected to grow in the coming years as more people become aware of the condition and demand for effective treatments increases.

North America Myopia Treatment Market Revenue and Forecast to 2030 (US$ Million)

Get more information on this report

North America Myopia Treatment Strategic Insights

Strategic insights for the North America Myopia Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/north-america-myopia-treatment-market-strategic-framework.webp

Get more information on this report

North America Myopia Treatment Report Scope

Report Attribute	Details
Market size in 2022	US$ 3,938.90 Million
Market Size by 2030	US$ 7,335.26 Million
Global CAGR (2022 - 2030)	8.1%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Type High Myopia Degenerative Myopia Progressive Myopia By Treatment Low-Dose Atropine Eye Drops Contact Lenses Ortho-K Refractive Surgery By End User Hospitals and Clinics Specialty Clinics Refractive Surgery Centers
Regions and Countries Covered	North America US Canada Mexico
Market leaders and key company profiles	Bausch Health Companies Inc Alcon AG CooperVision Inc Johnson & Johnson Vision Care Inc Topcon Healthcare Solutions Inc Ziemer Ophthalmic Systems AG Nidek Co Ltd Eyes Vision SL Haag-Streit AG Carl Zeiss AG

Get more information on this report

North America Myopia Treatment Regional Insights

The geographic scope of the North America Myopia Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

geography/north-america-myopia-treatment-market-geography.webp

Get more information on this report

North America Myopia Treatment Market Segmentation

The North America myopia treatment market is categorized into type, treatment, age group, end user, and country.

Based on type, the North America myopia treatment market is segmented into high myopia, degenerative myopia, and progressive myopia. The high myopia segment held the largest North America myopia treatment market share in 2022.

In terms of treatment, the North America myopia treatment market is segmented into low-dose atropine eye drops, contact lenses, ortho-k, and refractive surgery. The low-dose atropine eye drops segment held the largest North America myopia treatment market share in 2022. Furthermore, the refractive surgery segment is subcategorized into LASIK and PRK.

By age group, the North America myopia treatment market is bifurcated into adult myopia and childhood myopia. The adult myopia segment held a larger North America myopia treatment market share in 2022.

Based on end user, the North America myopia treatment market is categorized into hospitals and clinics, specialty clinics, and refractive surgery centers. The hospitals and clinics segment held the largest North America myopia treatment market share in 2022.

Based on country, the North America myopia treatment market is categorized into the US, Canada, and Mexico. The US dominated the North America myopia treatment market share in 2022.

Bausch Health Companies Inc, Alcon AG, CooperVision Inc, Johnson & Johnson Vision Care Inc, Topcon Healthcare Solutions Inc, Ziemer Ophthalmic Systems AG, Nidek Co Ltd, Eyes Vision SL, Haag-Streit AG, and Carl Zeiss AG. are some of the leading companies operating in the North America myopia treatment market.

Identical Market Reports with other Region/Countries